Clinical Trials in Detroit

Showing 8481-8500 of 19,719 trials

First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer

NCT04077021

CCW702 is an investigational immunotherapy for prostate cancer. This is a two-part, first-in-human study to assess the safety and tolerability of CCW702 administered subcutaneously to patients with metastatic, castration resistant prostate cancer. Part I is divided in to two subparts, in both subparts patients will receive ascending dosages of CCW702 with the goal to determine the maximum tolerated dose (MTD) of CCW702 and efficacious regimen. Part Ia will explore every other other day dosing (QOD); Part Ib will explore weekly dosing (Q7D). In part II of the study, patients will be given the recommended part/phase 2 dose (RP2D) Q7D. The study will also assess the pharmacokinetics and pharmacodynamics of CCW702.

Metastatic Castration-Resistant Prostate Adenocarcinoma

Calibr, a division of Scripps Research22 participantsStarted Jul 2020

San Diego, California, United States • Baltimore, Maryland, United States • Detroit, Michigan, United States +2 more locations

TERMINATEDPhase 1< 1 mile

First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD

NCT01728259

This phase I trial studies the side effects and best dose of pomalidomide and bortezomib when given together with dexamethasone in treating patients with amyloid light-chain amyloidosis or light chain deposition disease. Biological therapies, such as pomalidomide, may stimulate the immune system in different ways and stop abnormal cells from growing. Bortezomib may stop the growth of abnormal cells by blocking some of the enzymes needed for cell growth. Giving pomalidomide and bortezomib together with dexamethasone may be an effective treatment for amyloid light-chain amyloidosis or light chain deposition disease

Light Chain Deposition DiseasePrimary Systemic Amyloidosis

Barbara Ann Karmanos Cancer Institute18 participantsStarted Mar 2013

Denver, Colorado, United States • Boston, Massachusetts, United States • Detroit, Michigan, United States +2 more locations

First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer

First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD

Find Trials by Condition in Detroit

A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With Safety Run-in (innovaTV 208)

Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Severely Reduced Kidney Function Who Are Hospitalized for Coronavirus Disease 2019 (COVID-19)

rhBMP-2/CRM/CD HORIZON® Spinal System Pivotal Study

Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS)

ELUVIA™ Drug-eluting Stent Versus Zilver® PTX® Stent

Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Study of ASN003 in Subjects With Advanced Solid Tumors

A PRospective, rAndomizEd Comparison of subcuTaneOous and tRansvenous ImplANtable Cardioverter Defibrillator Therapy

Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis

P3 Long Term Safety Study of Once Daily SB204 in Acne

An Efficacy and Safety Study of Alirocumab in Children and Adolescents With Heterozygous Familial Hypercholesterolemia

A Trial of Alirocumab and Plaque Regression in Peripheral Arterial Disease

A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection

Study of TJ003234 (Anti-GM-CSF Monoclonal Antibody) in Subjects With Severe Coronavirus Disease 2019 (COVID-19)

MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035)

Kenota 1 CWS Method Comparison Validation Study

Subject Evaluation of a 1064nm Diode Laser/RF

Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB000928 in Participants With Impaired Renal Function and Hemodialysis